Patients with multiple myeloma are at an increased risk of venous thromboembolism and arterial thrombosis. We assessed the impact of venous and arterial thrombosis on survival in a population-based study of 9,399 multiple myeloma patients diagnosed in Sweden from 1987 to 2005. We found multiple myeloma patients with venous thromboembolism to have a higher mortality at 1-, 5-, and 10-years of follow up compared with those without, with hazard ratios of 2.9 (95% confidence interval (CI) 2.4-3.5), 1.6 (95% CI: 1.5-1.8), and 1.6 (95% CI: 1.4-1.7), respectively. There was an increase in risk of death among multiple myeloma patients with arterial thrombosis, with hazard ratios of 3.4 (95% CI: 3.0-3.8), 2.2 (95% CI: 2.0-2.3), and 2.1 (95% CI: 1.9-2.1), respectively. In landmark analyses at six months, early arterial but not venous thromboembolism was associated with a higher risk of death. Thus, in contrast to prior smaller studies, we found the development of thrombosis to be associated with significantly poorer survival. The prevention of thrombosis in multiple myeloma is an important goal in the management of these patients.
Notes
Cites: N Engl J Med. 2007 Nov 22;357(21):2123-3218032762
Cites: Int J Cancer. 2007 Nov 15;121(10):2260-617583571
Cites: Blood. 2008 Nov 1;112(9):3582-618559977
Cites: J Clin Oncol. 2010 Jan 1;28(1):132-519901114
Cites: J Clin Oncol. 2010 Feb 10;28(5):830-420038719
Cites: Blood. 2010 Jun 17;115(24):4991-820299513
Cites: Blood. 2010 Jul 8;116(1):22-620339094
Cites: Blood. 2010 Dec 16;116(25):5501-620823456
Cites: Hematology Am Soc Hematol Educ Program. 2010;2010:437-4421239832
Cites: N Engl J Med. 2000 Dec 21;343(25):1846-5011117976
Cites: N Engl J Med. 2001 Jun 21;344(25):1951-211419443